<DOC>
	<DOCNO>NCT00487682</DOCNO>
	<brief_summary>To investigate efficacy safety three different dos ASP2151 , compare valacyclovir hydrochloride subject herpes zoster , determine recommend clinical dose .</brief_summary>
	<brief_title>Dose-finding Study ASP2151 Subjects With Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Subjects age 20 year 80 year day inform consent obtain Subjects study drug orally administer within 72 hour onset rash due herpes zoster Subjects protocolspecified observation assessment consider possible Subjects extremely compromise immune function due underlying disease , treatment Immunosuppressive agent etc. , radiotherapy Subjects serious underlie disease corresponds Grade 3 Classification Criteria teh Seriousness Adverse Drug Reactions Subjects concurrent malignant tumor , history malignant tumor within past 5 year</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>herpes zoster</keyword>
	<keyword>ASP2151</keyword>
	<keyword>Valacyclovir hydrochloride</keyword>
</DOC>